Clinical remission by BMI in patients with severe eosinophilic asthma (SEA) over 1 year post benralizumab: real-world XALOC-2 programme

被引：0

作者：

Lommatzsch, Marek ^{[1
]}

Rothe, Thomas ^{[2
]}

Emmanuel, Benjamin ^{[3
]}

Tran, Trung N. ^{[3
]}

Menzies-Gow, Andrew ^{[4
]}

Shavit, Anat ^{[3
]}

Cohen, David ^{[3
]}

Ho, Calvin N. ^{[3
]}

Plate, Tanja ^{[5
]}

Kayaniyil, Sheena ^{[6
]}

Herreman, An ^{[7
]}

Schuoler, Claudio ^{[8
]}

Dupont, Lieven ^{[9
]}

Penz, Erika ^{[10
]}

机构：

[1] Univ Rostock, Rostock, Germany

[2] Cantonal Hosp GR Chur, Chur, Switzerland

[3] AstraZeneca, Gaithersburg, MD USA

[4] AstraZeneca, Cambridge, England

[5] AstraZeneca, Wedel, Germany

[6] AstraZeneca, Mississauga, ON, Canada

[7] AstraZeneca, Groot Bijgaarden, Belgium

[8] AstraZeneca, Baar, Switzerland

[9] Univ Hosp Leuven, Leuven, Belgium

[10] Univ Saskatchewan, Saskatoon, SK, Canada

来源：

EUROPEAN RESPIRATORY JOURNAL | 2024年 / 64卷

关键词：

D O I：

10.1183/13993003.congress-2024.PA3932

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

引用

页数：2

共 50 条

[41] Clinical remission in patients with severe eosinophilic asthma treated with benralizumab who were randomised to reduce their inhaled corticosteroid/formoterol dose: SHAMAL post-hoc analysis
Devouassoux, Gilles
Jackson, David J.
Kaessner, Frank F.
Caruso, Cristiano
Shavit, Anat
Olinger, Lynda
Menzies-Gow, Andrew
EUROPEAN RESPIRATORY JOURNAL, 2024, 64
[42] Pretreatment Frequency of Circulating Th17 Cells and FeNO Levels Predicted the Real-World Response after 1 Year of Benralizumab Treatment in Patients with Severe Asthma
Sandhu, Yuuki
Harada, Norihiro
Sasano, Hitoshi
Harada, Sonoko
Ueda, Shoko
Takeshige, Tomohito
Tanabe, Yuki
Ishimori, Ayako
Matsuno, Kei
Abe, Sumiko
Nagaoka, Tetsutaro
Ito, Jun
Chiba, Asako
Akiba, Hisaya
Atsuta, Ryo
Izuhara, Kenji
Miyake, Sachiko
Takahashi, Kazuhisa
BIOMOLECULES, 2023, 13 (03)
[43] Real-world Evidence of Improved Patient Outcomes With Reslizumab in Non-exacerbating Patients With Severe Eosinophilic Asthma (SEA): A Subgroup Analysis
Peters, Stephen
Wechsler, Michael
Chipps, Bradley
Hill, Tanisha
Ariely, Rinat
Depietro, Michael
Terasawa, Emi
Thomason, Darren
Panettieri, Reynold
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2020, 145 (02) : AB27 - AB27
[44] CLINICAL EFFECTIVENESS OVER 2 YEARS OF BENRALIZUMAB TREATMENT IN PATIENTS WITH SEVERE EOSINOPHILIC ASTHMA AND CONCOMITANT NASAL POLYPOSIS; ANALYSIS FROM THE BPAP STUDY
Jackson, D. J.
Burhan, H.
Pfeffer, P. E.
Clifton, I. J.
Faruqi, S.
Nanzer, A. M.
Dhariwal, J.
Morris, T.
Lupton, C.
Watt, M.
Rupani, H.
THORAX, 2023, 78 (SUPPL_4) : A186 - A186
[45] Real world clinical outcomes and remission rates among patients with severe asthma on monoclonal antibody therapy over two years
Fyles, Fred
Burton, Rachel
Nuttall, Amy
Cordha, Glen
Joplin, Hannah
Watkins, Laura
Burhan, Hassan
EUROPEAN RESPIRATORY JOURNAL, 2024, 64
[46] REAL-WORLD OUTCOMES WITH MEPOLIZUMAB IN PATIENTS WITH SEVERE EOSINOPHILIC ASTHMA ACCORDING TO SMOKING HISTORY AND COPD STATUS AT ENROLLMENT: REALITI-A POST HOC ANALYSIS
Bagnasco, Diego
Hill, David G.
Welte, Tobias
Chaudhuri, Rekha
Price, Robert
Howarth, Peter
CHEST, 2023, 164 (04) : 75A - 76A
[47] Mepolizumab Provides Real-World Clinical Benefits in Severe Eosinophilic Asthma Irrespective of Baseline Lung Function: Results From the REALITI-A Study at 2 Years
Bagnasco, D.
Pilette, C.
Lougheed, M.
Caruso, C.
Echave-Sustaeta, J.
Dennison, P.
Verghis, R.
Jakes, R.
Rais, M.
Howarth, P.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2023, 207
[48] Mepolizumab Demonstrates Real-world Clinical Effectiveness in both Type 2 Biomarker High and Type 2 Biomarker Low Patients with Severe Asthma
Chupp, Geoffrey
Lee, Jason
Liu, Mark
Schleich, Florence
Heaney, Liam
Domingo Ribas, Christian
Carrillo-Diaz, Teresa
Blanco Aparicio, Marina
Martinez Moragon, Eva
Guadalupe Sanchez-Herrero, M.
Gardiner, Frances
Alfonso-Cristancho, Rafael
Jakes, Rupert
Price, Robert
Howarth, Peter
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2022, 149 (02) : AB318 - AB318
[49] The impact of mepolizumab self-administration on real-world outcomes in patients with severe asthma: Post hoc analysis of REALITI-A at 2 years
Canonica, G. W.
Demetriou, L.
Schleich, F.
Pelaia, G.
Bernstein, D.
Lee, F. E. H.
Price, R. G.
Howarth, P.
ALLERGY, 2023, 78 : 185 - 186
[50] Real-World Evidence of Improved Patient Outcomes with Reslizumab in Adults with Severe Eosinophilic Asthma (SEA): Subgroup Analyses of Patients Using Maintenance Oral Corticosteroids (OCS) Prior to Treatment Initiation
Panettieri, Reynold
Wechsler, Michael
Peters, Stephen
Chipps, Bradley
Hill, Tanisha
Ariely, Rinat
Depietro, Michael
Terasawa, Emi
Thomason, Darren
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2020, 145 (02) : AB26 - AB26

← 1 2 3 4 5 →